<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02381444</url>
  </required_header>
  <id_info>
    <org_study_id>P14-322</org_study_id>
    <nct_id>NCT02381444</nct_id>
  </id_info>
  <brief_title>Health Related Quality of Life in LCIG Patients and LCIG Eligible Patients Continuing Oral Therapy</brief_title>
  <acronym>BALANCE</acronym>
  <official_title>Health Related Quality of Life in LCIG Patients and LCIG Patients and LCIG Eligible Patients Continuing Oral Therapy. A Multicenter Post Marketing Observational Study for LCIG in Germany and Switzerland - BALANCE</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to assess the effect of LCIG (levodopa-carbidopa intestinal gel) on
      HRQL (Health-Related Quality of Life) of participants and compare the Health-Related Quality
      of Life between participants continuing to levodopa-carbidopa intestinal gel treatments
      versus participants continuing on oral therapy for Parkinson's Disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Parkinson's disease (PD) is the second most common neurodegenerative disorder in the world.
      It can be treated sufficiently until motor complications with fluctuations of mobility and
      dyskinesia develop. The quality of life is relentlessly deteriorating with longer disease
      duration once the complications of conservative oral therapy develop. Continuous dopaminergic
      stimulation using Levodopa/Carbidopa Intestinal Gel (LCIG) improves the motor complications
      of Parkinson's disease and preliminary data suggest that also the quality of life is
      improved. Primary Objective is to assess the effect of LCIG on Health Related Quality of Life
      (HRQL) of patients according to selection criteria from German guidelines and compare
      improvement in HRQL between patients continuing to LCIG treatment and patients staying on
      oral treatment, despite being eligible according to these guidelines. In addition, current
      selection criteria recommended by the national guideline will be documented at baseline.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 17, 2015</start_date>
  <completion_date type="Actual">January 7, 2020</completion_date>
  <primary_completion_date type="Actual">January 7, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the Parkinson's Disease Questionnaire (PDQ-39) summary index</measure>
    <time_frame>From baseline to 12 months</time_frame>
    <description>The primary endpoint is the change in the Parkinson's Disease Questionnaire (PDQ-39) summary index from 12 months to the baseline assessment. The two treatment groups levodopa-carbidopa intestinal gel vs. Standard of Care will be compared.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Health Related Quality of Life (HRQL)</measure>
    <time_frame>At Baseline, 6, and 12 months of treatment</time_frame>
    <description>Unified Parkinson's disease Rating Scale (UPDRS) part III in the medication &quot;on&quot; state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in participant's motor symptoms</measure>
    <time_frame>From Baseline to 6 and 12 months of treatment.</time_frame>
    <description>Activities of daily living &quot;on&quot; and &quot;off&quot; medication - Unified Parkinson's disease Rating Scale (UPDRS) part II</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in participant's Healthcare Resource Utilization</measure>
    <time_frame>From Baseline to 6 and 12 months of treatment</time_frame>
    <description>Frequency and severity of ON-dyskinesia (Unified Parkinson's Disease Rating Scale part IV, Complications of Therapy: Items 32, 33, 34 and 39)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in participant's non-motor symptoms</measure>
    <time_frame>From baseline to 6 and 12 months of treatment</time_frame>
    <description>Non Motor Symptoms Scale (NMSS) Total score and subdomains Cardiovascular, Sleep/Fatigue, Gastrointestinal, Urinary, Sexual functioning</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reason for transition to LCIG (or continuing oral therapy)</measure>
    <time_frame>At Baseline, 6 and 12 month</time_frame>
    <description>There are no data comparing long-term HRQL of LCIG versus peroral therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in participant's caregiver burden</measure>
    <time_frame>From Baseline to 6 and 12 months of treatment</time_frame>
    <description>Non Motor Symptoms Scale (NMSS) Total score and subdomains Cardiovascular, Sleep/Fatigue, Gastrointestinal, Urinary, Sexual functioning</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">136</enrollment>
  <condition>Parkinson's Disease (PD)</condition>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <description>Participants with advanced Parkinson's Disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Levodopa Carbidopa Intestinal Gel</arm_group_label>
    <description>Participants with advanced Parkinson's Disease</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Advanced Parkinson Disease
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Eligibility for LCIG according to current version of the Summary of Product
             Characteristics of LCIG of the respective country (Germany, Switzerland).

          -  Decision to treat with LCIG or other medication made by the study physician prior to
             any decision to approach the patient to participate in this study.

          -  Unchanged available combinations of PD medicinal treatment for at least one week prior
             to study inclusion.

          -  Patient has given written informed consent.

        Exclusion Criteria:

          -  Contraindication to LCIG according to current version of the German SmPC or Swiss
             SmPC.

          -  Contraindication to placement of intrajejunal PEG-J tube.

          -  Current treatment with Deep Brain Stimulation (DBS), Apomorphine pump or LCIG

          -  Severe dementia based on a Mini-Mental State Examination (MMSE) of &lt; 10

          -  Acute psychotic disorder (benign hallucinations or earlier psychotic episodes are not
             an exclusion criterion)

          -  Depression with suicidal thoughts (earlier episodes of major depression are not an
             exclusion criterion)

          -  History or presence of any condition that might interfere with absorption,
             distribution, metabolism, or excretion of LCIG

          -  Drug or alcohol addiction (drug addiction: continuous or sporadic use of drugs without
             medical indication or with paradoxical medical indication or in inappropriate amounts.
             Addictive consumption of e.g. alcohol, cannabis, amphetamine, sniffing agents,
             cocaine, heroin, crack). Alcohol addiction male: &gt; 40 g/day; female: &gt; 30 g/day)

          -  Illiteracy or insufficient language skills to complete the questionnaires
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitaetsklinikum Aachen /ID# 204355</name>
      <address>
        <city>Aachen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniklinik Koln /ID# 148153</name>
      <address>
        <city>Köln</city>
        <state>Nordrhein-Westfalen</state>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johannes Wesling Klin Minden /ID# 151481</name>
      <address>
        <city>Minden</city>
        <state>Nordrhein-Westfalen</state>
        <zip>32429</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KH Martha-Maria Halle Dolau /ID# 144634</name>
      <address>
        <city>Halle (Saale)</city>
        <state>Sachsen-Anhalt</state>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Altenburger Land /ID# 139643</name>
      <address>
        <city>Altenburg</city>
        <zip>04600</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kliniken Beelitz GmbH /ID# 144633</name>
      <address>
        <city>Beelitz-heilstaetten</city>
        <zip>14547</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Delf, Berlin-Hoppegarten, DE /ID# 144632</name>
      <address>
        <city>Berlin-hoppengarten</city>
        <zip>15366</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kupsch, Berlin, DE /ID# 144840</name>
      <address>
        <city>Berlin</city>
        <zip>10627</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Puzich, Berlin, DE /ID# 148226</name>
      <address>
        <city>Berlin</city>
        <zip>10713</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Hospital Bremerhaven /ID# 144639</name>
      <address>
        <city>Bremerhaven</city>
        <zip>27574</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neuro Centrum Odenwald /ID# 206998</name>
      <address>
        <city>Erbach</city>
        <zip>64711</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herbst, Falkensee, DE /ID# 139642</name>
      <address>
        <city>Falkensee</city>
        <zip>14612</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Freiburg /ID# 144640</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik Haag /ID# 137458</name>
      <address>
        <city>Haag</city>
        <zip>83527</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wellach/Becker, Hamburg, DE /ID# 148228</name>
      <address>
        <city>Hamburg</city>
        <zip>22359</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diak.hospital Henriettenstift /ID# 148222</name>
      <address>
        <city>Hannover</city>
        <zip>30559</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KH Agatharied /ID# 144636</name>
      <address>
        <city>Hausham</city>
        <zip>83734</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Herford AdoeR /ID# 151482</name>
      <address>
        <city>Herford</city>
        <zip>32049</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Jena_Duplicate /ID# 152813</name>
      <address>
        <city>Jena</city>
        <zip>7747</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gertrudis-Klinik /ID# 144631</name>
      <address>
        <city>Leun-biskirchen</city>
        <zip>35638</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Magdeburg /ID# 163197</name>
      <address>
        <city>Magdeburg</city>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Philipps-Universitaet Marburg /ID# 116936</name>
      <address>
        <city>Marburg</city>
        <zip>35043</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kliniken Berg /ID# 151484</name>
      <address>
        <city>Tuebingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Zurich /ID# 153709</name>
      <address>
        <city>Zurich</city>
        <state>Zuerich</state>
        <zip>8006</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Luzerner Kantonsspital /ID# 153738</name>
      <address>
        <city>Luzern</city>
        <zip>6000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik Bethesda /ID# 153739</name>
      <address>
        <city>Tschugg BE</city>
        <zip>3233</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rehaklinik Zihlschlacht AG /ID# 153710</name>
      <address>
        <city>Zihlschlacht</city>
        <zip>8588</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Switzerland</country>
  </location_countries>
  <link>
    <url>http://rxabbvie.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 3, 2015</study_first_submitted>
  <study_first_submitted_qc>March 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 6, 2015</study_first_posted>
  <last_update_submitted>March 23, 2020</last_update_submitted>
  <last_update_submitted_qc>March 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced Parkinson's Disease</keyword>
  <keyword>Levodopa Carbidopa Intestinal Gel</keyword>
  <keyword>Observational Study</keyword>
  <keyword>Quality of life</keyword>
  <keyword>Jejunal Percutaneous Endoscopic Gastrostomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

